Purified cholera enterotoxin was prepared by methods described by Finkelstein and Lo Spalluto (1970) . This toxin was detoxified by treatment with heat and formaldehyde. Heating cholera toxin at 60 C for 25 min resulted in the formation of a polymer named procholeragenoid by Finkelstein et al. (1971) . The weak toxic activity of this product was removed by treatment with formalin. No residual toxicity could be demonstrated in formalinized procholeragenoid by the rabbit ileal loop assay and the highly sensitive rabbit skin test. This toxoid was nevertheless at least as antigenic in the rabbit as was the toxin. No reversion to toxicity was observed in vivo and in vitro at 4 C. The toxicity of formalinized procholeragenoid never exceeded 1/5,000 to 1/10,000 that of the toxin.
Studies in human volunteers (1) have shown that infection with Vibrio cholerae is followed by complete protection against a second challenge, but that vaccination with presently available cholera vaccines leads only to partial protection. During their illness, cholera patients develop antibodies against both the vibrio and the enterotoxin. Vaccination with whole-cell cholera vaccines induces only the formation of vibriocidal antibiodies (15) .
The protective value oftoxin-neutralizing antibodies has been shown in various animal models (5, 11, 18) .
The purpose of the present study was to develop a purified, antigenic cholera toxoid sufficiently detoxified and stable to be added to the presently available whole-cell vaccines. Methods for the in vitro production of cholera toxin (9) and for its purification (2, 9) and testing (3, 12) have been described. The usual method of detoxification with formaldehyde leads to a product that tends to revert in vitro and in vivo to toxicity (16) . Reacting cholera toxin with glutaraldehyde (19) yields a highly detoxified and stable product, but one that is only weakly antigenic without adjuvant (20) .
Finkelstein et al. (7) have described a "natural" toxoid, choleragenoid, and also a high-molecular-weight polymer, designated as procholeragenoid, that is an intermediate in the heat-mediated conversion of cholera toxin to choleragenoid. These two toxoids have been shown by Fujita and Finkelstein (10) to be highly immunogenic in animal models. In our preliminary studies, choleragenoid could be obtained only in low yields, whereas procholeragenoid was transformed quantitatively from purified choleragen. We therefore decided to develop a toxoid based on procholeragenoid.
MATERIALS AND METHODS
Production of purified toxin. V. cholerae strain Inaba 569B, obtained from N. K. Dutta via W. Burrows, was used in all these experiments. The toxin was produced in experimental fermenters of 10 to 200 liters. The syncase medium of Finkelstein and Lo Spalluto (9) was inoculated with 107 viable cells/ liter of an overnight culture and incubated under continuous stirring (550 rpm) at 30 C and aeration (1 liter/liter per min). After 17 h, the temperature was raised to 37 C and the culture was inactivated by the addition of 1 ml of a 10% thimerosal solution/liter. The cells were removed by centrifugation at 6,000 x g for 15 min in a Sorvall RC-3 centrifuge with the HG-4 rotor (4 x 1 liter) with a radius of 9.83 inches (about 24.6 cm). The toxin was concentrated and purified as described by Finkelstein and Lo Spalluto (9) by Al(OH)3 adsorption and elution.
Preparation of monospecific antiserum. Five adult male sheep and three goats were injected once in the hind legs with 1 mg of purified cholera toxin emulsified in complete Freund adjuvant. After 31 days blood samples were analyzed, and the animal (sheep no. 5911) with the lowest vibriocidal antibody titer was bled 42 days after receiving the immunizing toxin injection.
Immunochemical and chemical methods. The radial immunodiffusion technique of Mancini et al. (14) was used to make quantitative cholera toxin determinations.
Immunodiffusion assays by the Ouchterlony method were performed with the horse anticholeragen SSVI/EC-3 and the sheep anticholeragen 5911.
Immunoelectrophoresis was performed in a Spinco paper electrophoresis cell on glass plates (8.5 by 10 cm) with Noble agar (Difco), using a 0.01 M barbital buffer of pH 8.6 and 30 mA for 1 h. Antiserum EC-3 was added to the trough.
Acrylamide gel electrophoresis was performed by the method of Ornstein and Davis (17) .
Protein determinations were performed with the Lowry modification (13) of the Folin method; bovine serum albumin was used as a standard. 1692 PURIFIED ANTIGENIC CHOLERA TOXOID Determination of toxin activities. The cholera toxin potency of various toxin preparations was determined by the rabbit ileal loop (12) and skin assays (3) . Ileal loop activity was determined by the method of Kasai and Burrows (12) .
The skin vascular permeability potency was estimated by the limit-of-bluing titration method described by Craig et al. (3) .
Detoxification of cholera toxin. Cholera toxin in tris(hydroxymethyl)aminomethane-ethylenediamine tetraacetic acid (Tris-EDTA) buffer (6 mg/ml), pH 7.5, was heated for 25 min at 60 C. The Tris-EDTA buffer was then replaced with 0.1 M sodium borate buffer, pH 8.5 . Formaldehyde was added to the chilled solution to achieve a final concentration of 0.2%. After 60 h of incubation at 30 C, the remaining formaldehyde was removed by dialysis, the buffer was replaced by phosphate-buffered saline, and the toxoid concentration was adjusted to 1 mg of protein per ml.
Determination of antigenicity. Antigenicity of various toxin and toxoid preparations was determined by immunizing rabbits intramuscularly with 1 to 100 ,g of protein per kg of body weight. Four weeks later the rabbits received the same dose as a booster. The rabbits were then bled by heart puncture 4 and 6 weeks after the first injection. The antitoxin level in sera was determined by the intradermal neutralization test (3) . Serial dilutions of previously heated sera (30 min, 56 C) were incubated with an equal volume of a dilution of the crude toxin NIH-002, supplied by J. C. Feeley and containing 1 limit-of-bluing unit per ml. In each test the provisional standard antiserum EC-3, containing 4,470 antitoxin units per ml, was titrated.
Vibriocidal activity of sera was determined by the method of Finkelstein (4) .
Determination of immunogenicity. Immunogenicity was estimated according to Craig (2) and Rappaport et al. (19) on the basis of the suppression of bluing, which occurred when intramuscularly immunized guinea pigs were challenged by intradermal injection of serial dilutions of toxin.
Reversion tests. In vitro reversion was estimated by measuring the rabbit skin and ileal activity of toxoid samples kept for 4 In the first purification step, toxin was adsorbed from a cell-free culture on aluminum hydroxide and eluted with Tris-EDTA buffer, pH 8.2. The eluant was concentrated on a UM 20E ultrafilter and chromatographed on a column of Sephadex G-75. Three distinct peaks designated S-1, S-2, and S-3 were obtained. Fraction S-1 consisted mainly of lipopolysaccharides and nucleic acids; proteins were demonstrated only in minute amounts. This fraction showed no enterotoxic activity but was able to induce the production of vibriocidal antibodies in rabbits (Table 2 ). Fraction S-2 contained the cholera toxin, and fraction S-3 included the almost atoxic choleragenoid (Table   1 ).
Since preparation S-2 induced the production of vibriocidal antibodies (Table 2) , it was purified further by gel filtration on a column of agarose A-5m (8) . The toxin fraction (A-2) obtained by this chromatography consisted mainly of cholera toxin with trace amounts of In acrylamide gel electrophoresis (Fig. 1) , choleragenoid (S-3) was separated in three distinct bands, none of which was identical to the cholera toxin band. This phenomenon also has been described by Finkelstein and Lo Spalluto (8) . In our experiments, both the purified toxin preparations S-2 and A-2 and the reference cholera toxin of Finkelstein (lot 1071, prepared under contract for the National Institute of Allergy and Infectious Diseases and provided by R. Northrup) were separated in similar fashion in three bands.
Production of a monospecific antiserum. The SSVI antisera EC-3 and EC-8 were obtained in previous studies by repeated immunization of a horse with semipurified toxin preparations. Antiserum EC-3 was thoroughly titrated by J. P. Craig and has been proposed as a provisional standard antitoxin by the National Institutes of Health. In keeping with the immunization scheme, this serum contains antibodies against the toxin and also against various somatic antigens. It has been used in immunochemical tests to check the purity of toxin preparations.
The monospecific antiserum SSVI no. 5911 was obtained by immunizing a sheep with 1 mg of the purified toxin preparation (A-2). The level of toxin antibodies in antiserum no. 5911 was two to four times higher than that in antiserum EC-3 (Table 3 ). According to the immunization scheme (one single injection), it had a much lower avidity than EC-3. Vibriocidal activity could be demonstrated best up to a 1:10 dilution. Whereas antisera EC-3 and EC-8 gave four precipitin bands in Ouchterlony immunodiffusion against a semipurified toxin, antiserum no. 5911 exhibited only one precipitin line in this test (Fig. 2) . Similar results were obtained in immunoelectrophoresis tests.
Detoxification of cholera toxin. The heatmediated conversion of cholera toxin to choleragenoid proceeds through the high-molecularweight intermediate procholeragenoid (7) . Figure 3 shows the course of such a conversion. After only 2 min of exposure at 60 C, the three toxin bands had disappeared completely. No choleragenoid was formed during this period. The toxin band was replaced by a diffuse band that penetrated the soft 3.5% gel only slowly. At 20 min this band had concentrated into a dense band that failed to penetrate the separating gel. After this heating period, three distinct bands appeared in the choleragenoid region. Of the three bands, the upper one clearly dominated the other two. Further heating for 45 min resulted in the complete disappearance of the high-molecular-weight procholeragenoid band. of choleragen to procholeragenoid, as demonstrated by immunoelectrophoresis. After 5 min at 60 C, the cholera toxin was converted to procholeragenoid, which appeared as a dense precipitin band at the top of the wells. At 15 min, a new band appeared on the left; this consisted of choleragenoid. During the interval from 5 to 25 min, a precipitin band was also formed in the region of the choleragen. On the basis of the disc electrophoresis pattern (Fig. 3) as well as measurements of the toxin potency of these products, it can be concluded that this line could not be formed by incompletely transformed choleragen. Formaldehyde-treated procholeragenoid exhibited only one precipitin line in this assay.
Procholeragenoid produced in this way (25 min at 60 C) was only weakly active in the rabbit skin and the ileal loop assays (Table 4) . Various attempts to eliminate the remaining toxic activity by purification failed. It must be concluded that this remaining weak toxicity was not due to choleragen impurities but instead was inherent in the procholeragenoid.
The same conclusion could be drawn from the disc electrophoretic patterns (Fig. 3) . This weak residual toxicity of procholeragenoid was abol-1 2. 3:14 5 6 FIG. 3 . Acrylamide gel (3.5%) electrophoresis of cholera toxin (1) and oftoxin after 2 (2), 5 (3), 10 (4), 20 (5) , 25 (6), and 45 min (7) at 60 C.
ished by treatment with formaldehyde (Table   4) .
Stability of the formalinized procholeragenoid. Because of the known tendency of formaldehyde-detoxified choleragen to revert to partial toxicity, the formaldehyde-treated procholeragenoid also was checked for stability. Solutions of formalinized procholeragenoid (1 mg/ ml) were kept at 4 and 37 C and were assayed for toxin potency at 1 and 4 months ( Table 4 ).
In no case could any toxic activity be demonstrated in the ileal loop assay. Also, no reversion was demonstrated with the more sensitive skin test in samples kept for as long as 4 months at 4 C. Weak activity was demonstrated, however, with this assay in samples kept for 1 month at 37 C. Further incubation for another 3 months did not increase this activity. Toxic activity of formalinized procholeragenoid was never higher than 1/5,000 to 1/10,000 that of the toxin.
The possibility of in vivo reversion to toxicity VOL. 13, 1976 FIG. 4 . Immunoelectrophoresis of cholera toxin (CT) and oftoxin after 5,15, and 25 min at 60 C. FP, Formalin-treated procholeragenoid.
was studied by making a daily record for 2 weeks of induration diameters produced by an intracutaneous injection of 3 ,ug of formalinized procholeragenoid. Whereas a control injection of 3 ,ug of cholera toxin induced an induration of 15-to 17-mm diameter in the 2 to 3 days after application, injection of the same dose of formalin-treated procholeragenoid produced a small induration zone that never reached the 7-mm limit.
Antigenicity of formalinized procholeragenoid. By intramuscular immunization of rabbits with toxin and various toxoids in doses of 1 to 100 ,ug per kg of body weight, the potency of these preparations to elicit the formation of toxin-neutralizing antibodies was estimated (Table 5) . A good immune response could be obtained with as little as 1 ,ug/kg. With doses from 1 to 100 ,ug/kg, a good correlation existed between immunization dose and antibody titer. The toxoids choleragenoid and procholeragenoid were not significantly less antigenic, and the formaldehyde treatment did not reduce the antigenic potency of the procholeragenoid. Injection of a booster dose 4 weeks after the primary immunization resulted in a 10-to 20-fold increase in serum antitoxin level.
Storing the formalinized procholeragenoid at 4 and 37 C for 4 Similar results were observed when the immunogenicity of formalinized procholeragenoid was estimated in guinea pigs. Two groups of animals that were immunized with 1 and 10 ,tg of toxoid followed by a booster with the same dose after 4 weeks needed a 100-to 300-fold larger dose of toxin to produce an 8-mm bluing lesion (Table 6 ).
After immunizing rabbits with 100 ,.g of formalinized procholeragenoid, a weak but distinct rise in vibriocidal antibodies was observed (Table 2 ). Since the procholeragenoid used had been prepared from the toxin preparation S-2, this was not surprising. Obviously, the somatic antigens contained in this material were inactivated neither by heat (25 min at 60 C) nor by formaldehyde treatment. DISCUSSION Finkelstein (6) has reported the isolation of the cholera enterotoxin and of its "natural" toxoid, choleragenoid. Our semipurified cholera toxin preparations also contained important amounts of choleragenoid. This toxoid, which could not be demonstrated in culture filtrates, was formed in the course of toxin purification under certain circumstances such as aluminum hydroxide adsorption and elution. The conversion of choleratoxin to choleragenoid also could be produced under well-controlled conditions by heating at 60 C. In this process, the intermediary product procholeragenoid was also formed.
By limiting the heating to between 20 and 25 min, an almost quantitative conversion of choleragen to procholeragenoid was attained. Disc electrophoretic patterns indicate that the formation of the procholeragenoid proceeds through stages of intermediate aggregation.
Heating for 60 min resulted in complete conversion of procholeragenoid to choleragenoid.
Reversion of choleragenoid or procholeragenoid to higher toxicity was not observed. The residual toxicity of procholeragenoid was, like that of choleragenoid, reduced to at least 1/ 1,000 to 1/5,000 that of toxin. In the development of a toxoid vaccine, such a detoxification would not be sufficient. On the basis of results obtained by Craig et al. (3) in human volunteers, it can be estimated that parenteral appli- 4 weeks at 4 C did not produce reversion to higher toxicity. After storage for 4 weeks at 37 C, a weak toxic activity was demonstrated in the skin test; however, prolonged storage at 37 C did not result in an increase of this toxicity.
The antigenicity of the cholera toxin was not reduced by the detoxification procedures. Intramuscular injection of 1 to 100 ,g offormalinized procholeragenoid induced a dose-dependent production of toxin-neutralizing antibodies comparable to that induced by toxin. Administration of a booster dose resulted in an important rise in serum antibody level. Furthermore, it was shown that immunization with fonnalinized procholeragenoid can protect guinea pigs against a subsequent toxin-induced skin reaction. Besides a high titer of toxin-neutralizing antibodies, the toxoid described in this paper also induces, on a much lower level, the production of vibriocidal antibodies. We would like to emphasize that the purer toxin preparation A-2 can be used at any time to prepare, by toxoidation or by gel filtration of the procholeragenoid, a toxoid free of somatic antigens.
